Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Jun 05, 2025

Sun Pharma, Cipla Among Systematix' Top Picks in Healthcare Sector Post Inline Q4

Sun Pharma, Cipla Among Systematix' Top Picks in Healthcare Sector Post Inline Q4
Systematix revises rating on Pfizer and Jubilant Pharmova to Hold but maintian its price target.(Photo Source: freepik)
STOCKS IN THIS STORY
Zydus Lifesciences Ltd.
--
Pfizer Ltd.
--
Divis Laboratories Ltd.
--
Jubilant Pharmova Ltd.
--
Ajanta Pharma Ltd.
--
Orchid Pharma Ltd.
--
Cipla Ltd.
--
Indoco Remedies Ltd.
--
Sastasundar Ventures Ltd.
--
Sun Pharmaceutical Industries Ltd.
--

Pfizer and Divi's Laboratories outperformance was driven by better than expected revenue growth and margin expansion while Jubilant Pharmova, Dr. Reddy's and Zydus Lifesciences reported lower operational costs, thus aiding operating profit outperformance.

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Systematix Report

Companies under our coverage reported an in line Q4 FY25, with Divi Laboratories Ltd., Zydus Lifesciences, Pfizer, Dr. Reddy's Laboratories and Jubilant Pharmova Ltd. as outperformers on operating profit growth expectations and Indoco Remedies as the underperformer.

Pfizer and Divi's Laboratories outperformance was driven by better than expected revenue growth and margin expansion while Jubilant Pharmova, Dr. Reddy's and Zydus Lifesciences reported lower operational costs, thus aiding operating profit outperformance. However, Indoco Remedies underperformed expectations due to higher costs.

Our top picks are Sun Pharma, Cipla, Ajanta Pharma and Orchid Pharma. We discontinue coverage on Sastasundar Ventures and Indoco Remedies, considering the uncertainty around predicting their near term earnings owing to ongoing compliance challenges in case of Indoco Remedies and the transition of Sastasundar business into an online pharmacy.

Click on the attachment to read the full report:

Systematix India Healthcare - Q4 FY25 Result Review.pdf
VIEW DOCUMENT

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search